The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Human Cytomegalovirus Envelope Glycoprotein B Market Research Report 2024
Synopsis
The global Human Cytomegalovirus Envelope Glycoprotein B market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Human Cytomegalovirus Envelope Glycoprotein B is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Human Cytomegalovirus Envelope Glycoprotein B is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Human Cytomegalovirus Envelope Glycoprotein B include Astellas Pharma Inc., Trellis Bioscience, Inc., Vakzine Projekt Management GmbH, VBI Vaccine Inc and Vical Incorporated, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Human Cytomegalovirus Envelope Glycoprotein B, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Cytomegalovirus Envelope Glycoprotein B.
Report Scope
The Human Cytomegalovirus Envelope Glycoprotein B market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Cytomegalovirus Envelope Glycoprotein B market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Cytomegalovirus Envelope Glycoprotein B manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astellas Pharma Inc.
Trellis Bioscience, Inc.
Vakzine Projekt Management GmbH
VBI Vaccine Inc
Vical Incorporated
Segment by Type
CSJ-148
CyMVectin
TRL-345
PPCM
Cytomegalovirus Vaccine
Others
Segment by Application
Infectious Disease
Oncology
Women's Health
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Cytomegalovirus Envelope Glycoprotein B manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Cytomegalovirus Envelope Glycoprotein B in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Human Cytomegalovirus Envelope Glycoprotein B market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Human Cytomegalovirus Envelope Glycoprotein B is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Human Cytomegalovirus Envelope Glycoprotein B is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Human Cytomegalovirus Envelope Glycoprotein B include Astellas Pharma Inc., Trellis Bioscience, Inc., Vakzine Projekt Management GmbH, VBI Vaccine Inc and Vical Incorporated, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Human Cytomegalovirus Envelope Glycoprotein B, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Cytomegalovirus Envelope Glycoprotein B.
Report Scope
The Human Cytomegalovirus Envelope Glycoprotein B market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Cytomegalovirus Envelope Glycoprotein B market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Cytomegalovirus Envelope Glycoprotein B manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astellas Pharma Inc.
Trellis Bioscience, Inc.
Vakzine Projekt Management GmbH
VBI Vaccine Inc
Vical Incorporated
Segment by Type
CSJ-148
CyMVectin
TRL-345
PPCM
Cytomegalovirus Vaccine
Others
Segment by Application
Infectious Disease
Oncology
Women's Health
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Cytomegalovirus Envelope Glycoprotein B manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Cytomegalovirus Envelope Glycoprotein B in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Human Cytomegalovirus Envelope Glycoprotein B Market Overview
1.1 Product Overview and Scope of Human Cytomegalovirus Envelope Glycoprotein B
1.2 Human Cytomegalovirus Envelope Glycoprotein B Segment by Type
1.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Market Value Comparison by Type (2024-2030)
1.2.2 CSJ-148
1.2.3 CyMVectin
1.2.4 TRL-345
1.2.5 PPCM
1.2.6 Cytomegalovirus Vaccine
1.2.7 Others
1.3 Human Cytomegalovirus Envelope Glycoprotein B Segment by Application
1.3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Market Value by Application: (2024-2030)
1.3.2 Infectious Disease
1.3.3 Oncology
1.3.4 Women's Health
1.3.5 Others
1.4 Global Human Cytomegalovirus Envelope Glycoprotein B Market Size Estimates and Forecasts
1.4.1 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue 2019-2030
1.4.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales 2019-2030
1.4.3 Global Human Cytomegalovirus Envelope Glycoprotein B Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Human Cytomegalovirus Envelope Glycoprotein B Market Competition by Manufacturers
2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Manufacturers (2019-2024)
2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Human Cytomegalovirus Envelope Glycoprotein B Average Price by Manufacturers (2019-2024)
2.4 Global Human Cytomegalovirus Envelope Glycoprotein B Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Human Cytomegalovirus Envelope Glycoprotein B, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Human Cytomegalovirus Envelope Glycoprotein B, Product Type & Application
2.7 Human Cytomegalovirus Envelope Glycoprotein B Market Competitive Situation and Trends
2.7.1 Human Cytomegalovirus Envelope Glycoprotein B Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Human Cytomegalovirus Envelope Glycoprotein B Players Market Share by Revenue
2.7.3 Global Human Cytomegalovirus Envelope Glycoprotein B Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Human Cytomegalovirus Envelope Glycoprotein B Retrospective Market Scenario by Region
3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region: 2019-2030
3.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region: 2019-2024
3.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region: 2025-2030
3.3 Global Human Cytomegalovirus Envelope Glycoprotein B Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Region: 2019-2030
3.3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Region: 2019-2024
3.3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Region: 2025-2030
3.4 North America Human Cytomegalovirus Envelope Glycoprotein B Market Facts & Figures by Country
3.4.1 North America Human Cytomegalovirus Envelope Glycoprotein B Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2019-2030)
3.4.3 North America Human Cytomegalovirus Envelope Glycoprotein B Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Human Cytomegalovirus Envelope Glycoprotein B Market Facts & Figures by Country
3.5.1 Europe Human Cytomegalovirus Envelope Glycoprotein B Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2019-2030)
3.5.3 Europe Human Cytomegalovirus Envelope Glycoprotein B Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Market Facts & Figures by Country
3.6.1 Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2019-2030)
3.6.3 Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Human Cytomegalovirus Envelope Glycoprotein B Market Facts & Figures by Country
3.7.1 Latin America Human Cytomegalovirus Envelope Glycoprotein B Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2019-2030)
3.7.3 Latin America Human Cytomegalovirus Envelope Glycoprotein B Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Market Facts & Figures by Country
3.8.1 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2019-2030)
3.8.3 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Type (2019-2030)
4.1.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Type (2019-2024)
4.1.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Type (2025-2030)
4.1.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Type (2019-2030)
4.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Type (2019-2030)
4.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Type (2019-2024)
4.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Type (2025-2030)
4.2.3 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue Market Share by Type (2019-2030)
4.3 Global Human Cytomegalovirus Envelope Glycoprotein B Price by Type (2019-2030)
5 Segment by Application
5.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Application (2019-2030)
5.1.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Application (2019-2024)
5.1.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Application (2025-2030)
5.1.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Application (2019-2030)
5.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Application (2019-2030)
5.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Application (2019-2024)
5.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Application (2025-2030)
5.2.3 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue Market Share by Application (2019-2030)
5.3 Global Human Cytomegalovirus Envelope Glycoprotein B Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Astellas Pharma Inc.
6.1.1 Astellas Pharma Inc. Corporation Information
6.1.2 Astellas Pharma Inc. Description and Business Overview
6.1.3 Astellas Pharma Inc. Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Astellas Pharma Inc. Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
6.1.5 Astellas Pharma Inc. Recent Developments/Updates
6.2 Trellis Bioscience, Inc.
6.2.1 Trellis Bioscience, Inc. Corporation Information
6.2.2 Trellis Bioscience, Inc. Description and Business Overview
6.2.3 Trellis Bioscience, Inc. Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Trellis Bioscience, Inc. Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
6.2.5 Trellis Bioscience, Inc. Recent Developments/Updates
6.3 Vakzine Projekt Management GmbH
6.3.1 Vakzine Projekt Management GmbH Corporation Information
6.3.2 Vakzine Projekt Management GmbH Description and Business Overview
6.3.3 Vakzine Projekt Management GmbH Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Vakzine Projekt Management GmbH Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
6.3.5 Vakzine Projekt Management GmbH Recent Developments/Updates
6.4 VBI Vaccine Inc
6.4.1 VBI Vaccine Inc Corporation Information
6.4.2 VBI Vaccine Inc Description and Business Overview
6.4.3 VBI Vaccine Inc Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2019-2024)
6.4.4 VBI Vaccine Inc Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
6.4.5 VBI Vaccine Inc Recent Developments/Updates
6.5 Vical Incorporated
6.5.1 Vical Incorporated Corporation Information
6.5.2 Vical Incorporated Description and Business Overview
6.5.3 Vical Incorporated Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Vical Incorporated Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
6.5.5 Vical Incorporated Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Cytomegalovirus Envelope Glycoprotein B Industry Chain Analysis
7.2 Human Cytomegalovirus Envelope Glycoprotein B Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Cytomegalovirus Envelope Glycoprotein B Production Mode & Process
7.4 Human Cytomegalovirus Envelope Glycoprotein B Sales and Marketing
7.4.1 Human Cytomegalovirus Envelope Glycoprotein B Sales Channels
7.4.2 Human Cytomegalovirus Envelope Glycoprotein B Distributors
7.5 Human Cytomegalovirus Envelope Glycoprotein B Customers
8 Human Cytomegalovirus Envelope Glycoprotein B Market Dynamics
8.1 Human Cytomegalovirus Envelope Glycoprotein B Industry Trends
8.2 Human Cytomegalovirus Envelope Glycoprotein B Market Drivers
8.3 Human Cytomegalovirus Envelope Glycoprotein B Market Challenges
8.4 Human Cytomegalovirus Envelope Glycoprotein B Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
